FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 364 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Research shows one size doesn’t fit all for cervical screening in... May 17, 2021 Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma November 29, 2022 Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... January 25, 2024 Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... November 14, 2023 Load more HOT NEWS Cómo puede ayudar la terapia del piso pélvico a las personas... EMA Recommends Extension of Indications for Niraparib GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Poherdy
